| Objective:1.To study the incidence of sarcopenia in several tumors with higher morbidity,and to compare the occurrence of sarcopenia among different types of tumors.2.To further discuss the related influencing factors of tumor-associated sarcopenia,to increase the understanding of sarcopenia in cancer patients,and to achieve secondary prevention and early intervention for high-risk groups of tumor-associated sarcopenia.Methods:This study collected the clinical data of 1956 patients with different tumors who were diagnosed in the Bethune First Hospital of Jilin University from January 2013 to October 2016.We used the body composition analyzer to detect the appendicular skeletal mass(ASM).The muscle mass was assessed using the appendicular skeletal mass index(ASMI).The muscle strength was measured using handgrip strength dynamometer.According to the Asian Working Group for Sarcopenia(AWGS)diagnostic criteria for sarcopenia,we analyzed the difference of sarcopenia in different types of cancer patients,compared the differences in clinical characteristics,anthropometrics,and laboratory tests among patients with sarcopenia and non-sparsemic groups;and then discussed the related influencing factors of tumor-associated sarcopenia.Results:1.Of the 1956 cancer patients in this study,432 cases had sarcopenia,the incidence rate was 22.08%.Among them,the incidence of sarcopenia in gastric cancer was 38.80%(50/129);the colorectal cancer was 29.87%(118/395);the lung cancer was 19.35%(208/1075);the breast cancer was16.4%(31/189);the liver cancer was 11.9%(18/153);the pancreatic cancer was 41.2%(7/17).Except for the pancreatic cancer,there was statistical significance in the incidence of other types of tumors compared with the control group(P<0.05).2.The mean age of the sarcopenia group was higher[(62.61±10.18)years vs.(56.2±9.88)years,P<0.05]than that of the non-sarcopenia group;the BMI in the sarcopenia group was less[(19.91±2.58)kg/m~2 vs.(23.59±3.41)kg/m~2,P<0.05]than the non-sarcopenia group;the triglyceride levels in the sarcopenia group were lower[1.63(3.66)vs.2.35(3.69),P<0.05]than that in the non-muscle reduction group.There was no significant difference in gender,total protein,albumin,fasting blood glucose and cholesterol between the two groups(P>0.05).3.The incidence of sarcopenia was higher in gastrointestinal tumors than in non-gastrointestinal tumors[32.06%vs.18.44%,P<0.05].4.Further study on patients with gastrointestinal tumors,univariate analysis showed that the incidence of sarcopenia was statistically significant according to age,BMI score,KPS score,total protein,albumin,nutritional status and clinical stage(P<0.05).Further multivariate Logistic regression analysis showed that BMI and KPS scores were protective factors for sarcopenia in the patients with gastrointestinal tumors;age[OR=2.658,95%CI(1.665~4.244),P<0.05],and malnutrition[OR=3.420,95%CI(1.452~8.055),P<0.05]were independent risk factor for sarcopenia in the patients with gastrointestinal tumors tumor.Conclusion:1.The incidence rate of sarcopenia in 1956 tumor patients is 22.08%.There is statistical significance between the incidence of sarcopenia in different types of tumors,suggesting that the type of tumor is related to the incidence of sarcopenia.2.Compared with non-gastrointestinal tumors,the incidence rate of sarcopenia in gastrointestinal tumors is higher.3.Further study on patients with gastrointestinal tumors,BMI and KPS scores are protective factors for patients with sarcopenia;whereas age,malnutrition(PG-SGA score≥4 points)are independent risk factors for the occurrence of sarcopenia in cancer patients.Patients with advanced age,malnutrition,BMI<18.5,and KPS<70 should be screened as soon as possible for sarcopenia so that early prevention and timely treatment can be achieved. |
